Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Santen

This page shows the latest Santen news and features for those working in and with pharma, biotech and healthcare.

AbbVie's 'The Story of HS' wins at PMEA 2016

AbbVie's 'The Story of HS' wins at PMEA 2016

AbbVie picked up the prize for Excellence in Training Capability Development at the PMEA 2016 awards ceremony in London last week, seeing off competition from Novartis, Santen UK and Tillotts Pharma

Latest news

  • NICE no for new eye disease drug NICE no for new eye disease drug

    NICE's preliminary recommendation has been to ask Santen Pharmaceutical for more information on Ikervis (ciclosporin) for treating severe keratitis in adults with dry eye disease which has not improved despite

  • Antibiotics among 7 new drugs backed by EMA Antibiotics among 7 new drugs backed by EMA

    The final two drugs to feature in the list of positive opinions were Santen's Ikervis (ciclosporin) for the treatment of the eye condition severe keratitis and MDCO's Raplixa (human

  • US approval for Merck & Co’s eye drug Zioptan

    As part of the agreement between the two companies, Santen has the option to co-promote Zioptan in the US. ... In certain countries outside the US, Zioptan is sold as Saflutan by Merck and Tapros/ Taflotan by Santen.

  • Meeting with resistance

    Low-grade B-cell lymphoma; mantle cell lymphoma. Japan. Diquafosol. Diquas Ophthalmic Solution 3% (Santen Pharmaceutical).

  • Inspire drops cystic fibrosis programme

    net sales of Diquas (diquafosol) for dry eye, which is marketed in Japan by Santen but has not been approved in the US.

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    Ophthalmology. Ophthalmology is dominated by a small number of the same therapies marketed by different companies in different regions; Regeneron, Bayer and Santen all market Eylea, whereas Novartis and Roche market

  • Deal Watch table for May 2014 Deal Watch table for May 2014

    653. Merck &Co / Santen. Asset / product acquisition. 2. Ophthalmology products in Japan, Europe and Asia Pacific with sales of $400m.

  • Pharma deals during May 2014 Pharma deals during May 2014

    Not content with the Bayer deals, Merck &Co also divested its ophthalmic business (mainly Timolol) in Japan, Asia Pacific and Europe to its licensee Santen.

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    22. Tracon Pharmaceuticals/ Santen Pharmaceutical Co. Licence. Tracon's anti‐ endoglin antibodies, including TRC105 for wet AMD (p2).

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Luis Iglesias heads Santen EMEA Luis Iglesias heads Santen EMEA

    Luis Iglesias has been promoted as Santen’s EMEA head, a move that sees him succeed Shigeo Taniuchi - who returns to Japan to become president and chief operating office of parent ... Iglesias initially joined Santen in 2017 as its senior vice president

  • Paolo Casati named as general manager of Santen Italy Paolo Casati named as general manager of Santen Italy

    Paolo Casati named as general manager of Santen Italy. Has over 30 years of experience in the sector. ... Eye care specialist Santen Pharma has appointed Paolo Casati as general manager of its Italian subsidiary.

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Quick links

Infographics

Multimedia